Microparticles reveal cell activation during IVF – a possible early marker of a prothrombotic state during the first trimester

Nina Olausson; Fariborz Mobarrez; Håkan Wallen; Eli Westerlund; Outi Hovatta; Peter Henriksson

doi:10.1160/TH15-12-0970

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2016; 116(03): 517-523
DOI: 10.1160/TH15-12-0970

Cellular Haemostasis and Platelets

Schattauer GmbH

Microparticles reveal cell activation during IVF – a possible early marker of a prothrombotic state during the first trimester

Nina Olausson

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden

,

Fariborz Mobarrez

²Karolinska Institutet, Department of Medicine Solna, Unit of Rheumatology, Karolinska University Hospital, Stockholm, Sweden

,

Håkan Wallen

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden

,

Eli Westerlund

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden

,

Outi Hovatta

³Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Stockholm, Sweden

,

Peter Henriksson

¹Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden

› Institutsangaben

Abstract

Summary

Cell-derived microparticles (MPs) are known to be elevated in a number of diseases related to arterial and venous thromboembolism (VTE), such as acute myocardial infarction, VTE (deep-vein thrombosis and pulmonary embolism) and peripheral arterial disease. IVF-associated pregnancies have previously been shown to be associated with an increased incidence of VTE, mechanisms behind being unknown and sparsely studied. Our objective was to assess cell activation during IVF through analysis of MP levels and phenotype following ovarian stimulation. Thirty-one women undergoing IVF were included and blood samples were collected at down regulation of oestrogen and at high level stimulation with 10- to 100-fold increased endogenous oestrogen levels. MPs were analysed by flow cytometry and phenotyped according to size and protein expression. We found that overall phosphatidylserine positive platelet-, endothelial- and monocyte-derived MPs significantly increased following ovarian stimulation with increased levels of platelet activation markers CD40 ligand and P-selectin. Furthermore, there was an increase in endothelial-derived MPs exposing activation marker E-selectin and monocyte-derived MPs, while neutrophil-derived MPs decreased slightly. In conclusion we found a major increase in MPs and markers indicating cell activation in parallel with the profound oestrogen boost during IVF. To assess whether these changes in MPs are associated with thromboembolic events requires extended longitudinal studies.

Keywords

Cell-derived microparticles - oestrogen - in vitro fertilisation - IVF - venous thromboembolism

Volltext

Referenzen

References
1 Henriksson P, Westerlund E, Wallen H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. Br Med J 2013; 346: e8632.
2 Pomp ER, Lenselink AM, Rosendaal FR. et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637.
3 Rova K, Passmark H, Lindqvist PG.. Venous thromboembolism in relation to in vitro fertilisation: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012; 97: 95-100.
4 Khan KS, Wojdyla D, Say L. et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074.
5 Aksu K, Donmez A, Keser G.. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 2012; 18: 1478-1493.
6 Nomura S, Shimizu M.. Clinical significance of procoagulant microparticles. J Intensive Care 2015; 3: 2.
7 Mobarrez F, He S, Broijersen A. et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
8 Westerlund E, Henriksson P, Wallen H. et al. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilisation with global assays of haemostasis. Thromb Res 2012; 130: 649-653.
9 Westerlund E, Antovic A, Hovatta O. et al. Changes in von Willebrand factor and ADAMTS13 during IVF. Blood Coagul Fibrinolysis 2011; 22: 127-131.
10 Aune B, Hoie KE, Oian P. et al. Does ovarian stimulation for in-vitro fertilisation induce a hypercoagulable state?. Hum Reprod 1991; 6: 925-927.
11 Bremme K, Wramsby H, Andersson O. et al. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation?. Blood Coagul Fibrinolysis 1994; 5: 205-210.
12 Kim HC, Kemmann E, Shelden RM. et al. Response of blood coagulation parameters to elevated endogenous 17 beta-estradiol levels induced by human me-nopausal gonadotropins. Am J Obstet Gynecol 1981; 140: 807-810.
13 Andersson O, Blomback M, Bremme K. et al. Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation. Thromb Haemost 1997; 77: 901-904.
14 Lox C, Canez M, Prien S.. The influence of hyperestrogenism during in vitro fertilisation on the fibrinolytic mechanism. Int J Fertil Womens Med 1998; 43: 34-39.
15 Rice VC, Richard-Davis G, Saleh AA. et al. Fibrinolytic parameters in women undergoing ovulation induction. Am J Obstet Gynecol 1993; 169: 1549-1553.
16 Burger D, Schock S, Thompson CS. et al. Microparticles: biomarkers and beyond. Clin Sci 2013; 124: 423-441.
17 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
18 Orvieto R.. Controlled ovarian hyperstimulation--an inflammatory state. J Soc Gynecol Investig 2004; 11: 424-426.
19 Biron C, Galtier-Dereure F, Rabesandratana H. et al. Hemostasis parameters during ovarian stimulation for in vitro fertilisation: results of a prospective study. Fertil Steril 1997; 67: 104-109.
20 Theoret JF, Yacoub D, Hachem A. et al. P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. Thromb Res 2011; 128: 243-250.
21 Jenne CN, Urrutia R, Kubes P.. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 2013; 35: 254-261.
22 Akarasereenont P, Tripatara P, Chotewuttakorn S. et al. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets 2006; 17: 441-447.
23 Richard-Davis G, Montgomery-Rice V, Mammen EF. et al. In vitro platelet function in controlled ovarian hyperstimulation cycles. Fertil Steril 1997; 67: 923-927.
24 Rank A, Nieuwland R, Nikolajek K. et al. Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women. Arch Gynecol Obstet 2012; 285: 1035-1041.
25 Orvieto R, Schachter B, Yulzari-Roll V. et al. Soluble CD40 ligand levels during controlled ovarian hyperstimulation--a possible culprit of systemic inflammation. Am J Reprod Immunol 2006; 56: 243-248.
26 Yong PJ, Koh CH, Shim WS.. Endothelial microparticles: missing link in endothelial dysfunction?. Eur J Prev Cardiol 2013; 20: 496-512.
27 Molloy EJ, O’Neill AJ, Grantham JJ. et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003; 102: 2653-2659.
28 Muller WA.. How endothelial cells regulate transmigration of leukocytes in the inflammatory response. Am J Pathol 2014; 184: 886-896.